

At page 13, line 1, insert --- SEQ ID NO:2 --- after "RID α -S"; at line 2, insert --- (SEQ ID NO:1) --- after "RID α -L", and insert --- (SEQ ID NO:4) --- between "Ad5" and the period "." at the end of the line.

After the pages of drawings, please add the Sequence Listing, consisting of pages separately numbered 1 - 11. ✓

IN THE CLAIMS:

Please amend the claims as follows: ✓

Q2 Sub B1 1. (Amended) A method for inhibiting apoptosis of a cell comprising treating the cell with an effective amount of a Receptor Internalization and Degradation (RID) complex having a RID α polypeptide and a RID β polypeptide.

Q3 Sub B4 10. (Amended). A method for ~~decreasing apoptosis of target cells in a patient~~ comprising treating the patient with an effective amount of a Receptor Internalization and Degradation (RID) complex having a RID α polypeptide and a RID β polypeptide.

Q4 Sub B6 17. (Amended) A method for decreasing leukocyte apoptosis in a patient comprising:
(1) withdrawing leukocytes from the patient,
(2) treating the leukocytes with an effective amount of a RID complex having a RID α polypeptide and a RID β polypeptide, and
(3) administering the treated leukocytes to the patient.

Q5 Sub B8 23. (Amended) A composition comprising a Receptor Internalization and Degradation (RID) complex and a pharmaceutically acceptable excipient, where the RID complex includes a RID α polypeptide and a RID β polypeptide. [and a carrier suitable for facilitating delivery of the RID complex into a cell.]

24. (Amended) A recombinant adenovirus comprising a polynucleotide encoding a Receptor Internalization and Degradation (RID) complex having a RID α polypeptide and a RID β polypeptide, which RID complex is operably linked to a promoter, wherein the adenovirus is replication defective and wherein the polynucleotide is expressed upon infection of a eukaryotic cell with the adenovirus.